Skip to main content
Luke Pike, MD, Radiation Oncology, New York, NY

LukeRoy GeorgPikeMDDPhil

Radiation Oncology New York, NY

Assistant Attending / Assistant Professor

Overview of Dr. Pike

Dr. Luke Pike is a radiation oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Boston Children's Hospital. He received his medical degree from Yale School of Medicine and has been in practice 1 year. He is one of 8 doctors at Boston Children's Hospital and one of 106 doctors at Memorial Sloan Kettering Cancer Center who specialize in Radiation Oncology. He has more than 40 publications and over 500 citings.

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalInternship, Preliminary Year, 2015 - 2016
  • Yale School of Medicine
    Yale School of MedicineClass of 2015
  • Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2023 - Present
  • NY State Medical License
    NY State Medical License 2020 - 2026
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • MA State Medical License
    MA State Medical License 2015 - 2022
  • American Board of Radiology Radiation Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • The impact of race and socioeconomic status on outcomes for HPV-associated squamous cell carcinoma of the head and neck. 
    ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Press Mentions

  • Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part II)
    Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part II)September 18th, 2024
  • Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part I)
    Evaluating Stereotactic Radio Surgery plus TKI vs TKI Alone Among Patients with Brain Metastases from EGFR- and ALK-Altered NSCLC (Part I)September 5th, 2024
  • MSK Research Highlights, August 13, 2024
    MSK Research Highlights, August 13, 2024August 13th, 2024
  • Join now to see all